| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
2
|
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
|
Clin Cancer Res
|
2009
|
2.90
|
|
3
|
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
|
J Clin Oncol
|
2008
|
2.66
|
|
4
|
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
|
J Clin Endocrinol Metab
|
2006
|
1.77
|
|
5
|
Persistent pain in postmastectomy patients: comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain.
|
Pain
|
2012
|
1.62
|
|
6
|
Comorbidity as a mediator of survival disparity between younger and older women diagnosed with metastatic breast cancer.
|
Hypertension
|
2011
|
1.48
|
|
7
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
|
J Clin Oncol
|
2005
|
1.41
|
|
8
|
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
|
Cancer Invest
|
2004
|
1.33
|
|
9
|
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
|
Clin Cancer Res
|
2012
|
1.27
|
|
10
|
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
|
J Natl Cancer Inst
|
2010
|
1.26
|
|
11
|
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
|
Clin Cancer Res
|
2012
|
1.26
|
|
12
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
Breast Cancer Res Treat
|
2008
|
1.21
|
|
13
|
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
|
Cancer
|
2006
|
1.13
|
|
14
|
Inhibin-B levels in healthy young adult men and prepubertal boys: is obesity the cause for the contemporary decline in sperm count because of fewer Sertoli cells?
|
J Androl
|
2006
|
1.12
|
|
15
|
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
|
J Clin Oncol
|
2008
|
1.12
|
|
16
|
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2014
|
1.10
|
|
17
|
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.
|
Mod Pathol
|
2008
|
1.08
|
|
18
|
Patient preferences for chemotherapies used in breast cancer.
|
Int J Womens Health
|
2012
|
1.04
|
|
19
|
Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors.
|
J Pain
|
2013
|
1.01
|
|
20
|
Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
|
Am J Surg Pathol
|
2008
|
0.98
|
|
21
|
NCCN Task Force Report: Bone Health and Cancer Care.
|
J Natl Compr Canc Netw
|
2006
|
0.96
|
|
22
|
Factors associated with mortality after breast cancer metastasis.
|
Cancer Causes Control
|
2011
|
0.95
|
|
23
|
Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
|
Arch Pathol Lab Med
|
2006
|
0.93
|
|
24
|
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
|
Breast Cancer Res
|
2011
|
0.92
|
|
25
|
Understanding and optimizing bone health in breast cancer.
|
Curr Med Res Opin
|
2010
|
0.92
|
|
26
|
The effect of delays in treatment for breast cancer metastasis on survival.
|
Breast Cancer Res Treat
|
2011
|
0.90
|
|
27
|
Biomarker profile in breast carcinomas presenting with bone metastasis.
|
Int J Clin Exp Pathol
|
2009
|
0.88
|
|
28
|
A case of late-onset gemcitabine lung toxicity.
|
Clin Med Insights Oncol
|
2011
|
0.86
|
|
29
|
An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration.
|
J Biol Chem
|
2013
|
0.85
|
|
30
|
Adjuvant endocrine therapy for premenopausal women with breast cancer.
|
Breast
|
2009
|
0.85
|
|
31
|
Lymphedema prevention and early intervention: a worthy goal.
|
Oncology (Williston Park)
|
2012
|
0.84
|
|
32
|
The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity.
|
Oncol Nurs Forum
|
2011
|
0.79
|
|
33
|
Bisphosphonates in breast cancer: a triple winner?
|
Oncology (Williston Park)
|
2015
|
0.78
|
|
34
|
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
|
Urology
|
2003
|
0.78
|
|
35
|
Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases.
|
Int J Surg Oncol
|
2010
|
0.78
|
|
36
|
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
|
Biologics
|
2008
|
0.78
|
|
37
|
Challenges of illness in metastatic breast cancer: a low-income African American perspective.
|
Palliat Support Care
|
2009
|
0.77
|
|
38
|
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
|
J Immunol
|
2006
|
0.77
|
|
39
|
Treatment of HER2-positive breast cancer: looking backwards briefly.
|
Lancet Oncol
|
2013
|
0.76
|
|
40
|
Precision oncology in breast cancer: better than ever, or less than before?
|
Breast J
|
2013
|
0.76
|
|
41
|
Bisphosphonates do not reduce breast cancer in postmenopausal women.
|
Ann Intern Med
|
2015
|
0.75
|
|
42
|
Bevacizumab in breast cancer: the best is yet to come?
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
43
|
Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer.
|
J Natl Cancer Inst
|
2009
|
0.75
|
|
44
|
Metastatic breast cancer or multiple myeloma? Camouflage by lytic lesions.
|
J Oncol
|
2010
|
0.75
|
|
45
|
Metastasis of breast carcinoma to the maxillary sinus.
|
Breast J
|
2014
|
0.75
|